PMID- 23292040
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20211021
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 270
IP  - 4
DP  - 2013 Mar
TI  - The effect of itopride combined with lansoprazole in patients with 
      laryngopharyngeal reflux disease.
PG  - 1385-90
LID - 10.1007/s00405-012-2341-8 [doi]
AB  - The objective of this study is to determine the efficacy of adding a prokinetic 
      agent to proton pump inhibitors (PPI) for the treatment of laryngopharyngeal 
      reflux (LPR) disease. A prospective, randomized open trial comparing lansoprazole 
      plus itopride to lansoprazole single therapy was performed for 12 weeks. 
      Sixty-four patients with a reflux finding score (RFS) >7 and a reflux symptom 
      index (RSI) >13 were enrolled and received either lansoprazole 30 mg once daily 
      with itopride 50 mg three times daily or lansoprazole 30 mg once daily for 12 
      weeks. RSI and RFS were completed at baseline, after 6 weeks, and after 12 weeks. 
      During the treatment period, RSI and RFS were significantly improved compared 
      with the pretreatment scores in both study groups. Reductions of total RSI and 
      globus symptom were significantly higher in the lansoprazole plus itopride group 
      compared to the lansoprazole group. In the RFS, however, there were no 
      significant differences between the two groups. In conclusion, itopride in 
      addition to PPI did not show any superior RFS improvement compared to PPI single 
      therapy, but was helpful in speeding up relief of reflux symptoms in LPR 
      patients. Thus, itopride may be considered as the secondary additive agent in the 
      PPI treatment of LPR patients.
FAU - Chun, Byung-Joon
AU  - Chun BJ
AD  - Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, Korea. bj1000@catholic.ac.kr
FAU - Lee, Dong-Soo
AU  - Lee DS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130105
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzamides)
RN  - 0 (Benzyl Compounds)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 81BMQ80QRL (itopride)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Benzamides/*therapeutic use
MH  - Benzyl Compounds/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lansoprazole
MH  - Laryngopharyngeal Reflux/*drug therapy
MH  - Laryngoscopy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Young Adult
EDAT- 2013/01/08 06:00
MHDA- 2013/10/01 06:00
CRDT- 2013/01/08 06:00
PHST- 2012/09/25 00:00 [received]
PHST- 2012/12/18 00:00 [accepted]
PHST- 2013/01/08 06:00 [entrez]
PHST- 2013/01/08 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
AID - 10.1007/s00405-012-2341-8 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1385-90. doi: 
      10.1007/s00405-012-2341-8. Epub 2013 Jan 5.